LONDON—The biotech startup guiding the Covid-19 vaccine jointly produced by AstraZeneca PLC and the College of Oxford filed Friday with U.S. regulators for a general public share presenting.

Vaccitech PLC explained in a securities filing it designs to use the technological innovation underpinning the vaccine to establish treatments focusing on prostate most cancers, hepatitis B and human papillomavirus. The Wall Road Journal documented Wednesday that the IPO filing could occur as before long as this week. The U.K.-dependent company strategies to record on New York’s Nasdaq with the ticker image VACC.

The business was begun by two Oxford scientists who aided direct the Covid-19 vaccine growth and who spun Vaccitech out of the college in 2016, with the goal of turning laboratory discoveries into business goods. A crucial part of the vaccine technology takes advantage of an altered type of chimpanzee cold virus to ferry genetic product into people to enhance the immune system and battle infection.

Vaccitech has been aiming for a listed valuation of close to $700 million, with backers estimating it could be a $1 billion business by yr-end, The Journal documented final month.  The corporation a short while ago elevated $168 million in new funding as a stage toward a share providing.

It experienced $4.8 million in revenue final calendar year and a decline of about $17.7 million and has not generated any earnings from products gross sales, in accordance to Friday’s filing. It reported Vaccitech aims to increase $100 million—a determine usually set in debut IPO filings as a placeholder to be modified in the course of promoting of the firm.